GlassScriptPhysician profile
Kelly M Pseres
NPI 1679883201
$5,865.85
in general payments reported to CMS, 2019-2025
25 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 96% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
See the full distribution for General Practice (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $672 · 2022: $1,259 · 2023: $1,240 · 2024: $1,348 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Travel and Lodging: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.23 |
| Travel and Lodging | $535.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intrinsic Therapeutics | $1,005.00 | 2025 | Barricaid Acd (Annular Closure Device) |
| Teva Pharmaceuticals USA, INC. | $932.54 | 2021-2024 | Ajovy, Austedo Xr |
| Amgen INC. | $483.51 | 2022-2025 | Evenity, Repatha, Prolia |
| Alexion Pharmaceuticals, INC. | $339.71 | 2022-2024 | Soliris |
| Nevro Corp. | $336.82 | 2023-2024 | Senza |
| Novo Nordisk INC | $269.00 | 2022-2025 | Wegovy |
| Medical Device Business Services, INC. | $235.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $208.38 | 2021-2022 | |
| Medtronic, INC. | $166.65 | 2023 | Interstim, Intellis Adaptivestim |
| Si-Bone, INC. | $150.78 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $145.55 | 2023 | Persona, Arcos |
| Inspire Medical Systems, INC. | $141.92 | 2023 | Inspire |
| Silk Road Medical, INC. | $141.60 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Edwards Lifesciences Corporation | $128.75 | 2021 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $124.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2024 | Rexulti |
| Pfizer INC. | $122.87 | 2024 | |
| Alnylam Pharmaceuticals INC. | $121.82 | 2023 | Amvuttra |
| Abbott Laboratories | $120.78 | 2022 | |
| Ethicon US, LLC | $114.38 | 2022 | |
| Orthofix Medical, INC. | $106.65 | 2024 | 7d Surgical System |
| Kuros Biosciences USA, INC | $75.69 | 2021-2022 | |
| Boston Scientific Corporation | $18.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Pseres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.